Rereading the NY Times article that created such a flurry of comments last night. Realizing that the difficulty with trial enrollment would impact Cytodyn as well, particularly if they need to do a Phase 3 in m/m, as mildly ill people are reluctant to accept experimental treatments. One would think that, knowing this, the FDA would be more inclined to grant EUA based on the already completed trial data and proven safety.

Fingers crossed.